論文

国際誌
2022年

Head and neck small-cell carcinoma: A multicenter study of 39 cases from 10 institutions.

Frontiers in surgery
  • Hiroshi Matsuyama
  • Yushi Ueki
  • Isaku Okamoto
  • Toshitaka Nagao
  • Kohei Honda
  • Keisuke Yamazaki
  • Ryuichi Okabe
  • Takafumi Togashi
  • Ryusuke Shodo
  • Hisayuki Ota
  • Takeshi Takahashi
  • Jo Omata
  • Yusuke Yokoyama
  • Kohei Saijo
  • Ryoko Tanaka
  • Kiyoaki Tsukahara
  • Tadashi Kitahara
  • Hirokazu Uemura
  • Seiichi Yoshimoto
  • Fumihiko Matsumoto
  • Kenji Okami
  • Akihiro Sakai
  • Kenichi Takano
  • Atsushi Kondo
  • Hidenori Inohara
  • Hirotaka Eguchi
  • Nobuhiko Oridate
  • Teruhiko Tanabe
  • Munenaga Nakamizo
  • Kazuhiko Yokoshima
  • Koki Miura
  • Yosuke Kitani
  • Arata Horii
  • 全て表示

9
開始ページ
1049116
終了ページ
1049116
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.3389/fsurg.2022.1049116

OBJECTIVE: Basal information of head and neck small-cell carcinoma (HNSmCC) including epidemiology, primary site, treatment, and prognosis remains sparse due to its rarity. We report here a multicenter retrospective study on the diagnosis, treatment, and outcomes of patients with HNSmCC. MATERIALS AND METHODS: This study involved 47 patients with HNSmCC from 10 participating institutions. Eight patients were excluded for whom no pathological specimens were available (n = 2) and for discrepant central pathological judgements (n = 6). The remaining 39 patients were processed for data analysis. RESULTS: As pretreatment examinations, computed tomography (CT) was performed for the brain (n = 8), neck (n = 39), and chest (n = 32), magnetic resonance imaging (MRI) for the brain (n = 4) and neck (n = 23), positron emission tomography-CT (PET-CT) in 23 patients, bone scintigraphy in 4, neck ultrasonography in 9, and tumor markers in 25. Primary sites were oral cavity (n = 1), nasal cavity/paranasal sinuses (n = 16), nasopharynx (n = 2), oropharynx (n = 4), hypopharynx (n = 2), larynx (n = 6), salivary gland (n = 3), thyroid (n = 2), and others (n = 3). Stages were II/III/IV-A/IV-B/IV-C/Not determined = 3/5/16/6/5/4; stage IV comprised 69%. No patient had brain metastases. First-line treatments were divided into 3 groups: the chemoradiotherapy (CRT) group (n = 27), non-CRT group (n = 8), and best supportive care group (n = 4). The CRT group included concurrent CRT (CCRT) (n = 17), chemotherapy (Chemo) followed by radiotherapy (RT) (n = 5), and surgery (Surg) followed by CCRT (n = 5). The non-CRT group included Surg followed by RT (n = 2), Surg followed by Chemo (n = 1), RT alone (n = 2), and Chemo alone (n = 3). The 1-year/2-year overall survival (OS) of all 39 patients was 65.3/53.3%. The 1-year OS of the CRT group (77.6%) was significantly better compared with the non-CRT group (31.3%). There were no significant differences in adverse events between the CCRT group (n = 22) and the Chemo without concurrent RT group (n = 9). CONCLUSION: Neck and chest CT, neck MRI, and PET-CT would be necessary and sufficient examinations in the diagnostic set up for HNSmCC. CCRT may be recommended as the first-line treatment. The 1-year/2-year OS was 65.3%/53.3%. This study would provide basal data for a proposing the diagnostic and treatment algorithms for HNSmCC.

リンク情報
DOI
https://doi.org/10.3389/fsurg.2022.1049116
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/36451679
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701733
ID情報
  • DOI : 10.3389/fsurg.2022.1049116
  • PubMed ID : 36451679
  • PubMed Central 記事ID : PMC9701733

エクスポート
BibTeX RIS